相关实验视频
Updated: Jun 23, 2025

13:45
Merkel Cell Polyomavirus Infection and Detection
Published on: February 7, 2019
9.9K
默克尔细胞多瘤病毒向SET/PP2A复合体,以促进细胞增殖和迁移
Purnima Gupta1, Assunta Venuti1, Michelle Savoldy2
1International Agency for Research on Cancer, Lyon, France.
Virology
|June 25, 2024
概括
研究人员确定了SET蛋白作为默克尔细胞癌 (MCC) 的关键调节者,这是一种罕见的皮肤癌. 向SET蛋白对开发新的MCC治疗有望通过抑制瘤生长来实现.
科学领域:
- 在瘤学瘤学.
- 分子生物学分子生物学
- 皮肤病学 皮肤病学
背景情况:
- 默克尔细胞癌 (MCC) 是一种罕见的,侵袭性的神经内分泌性皮肤癌.
- 之前的研究发现NDRG1对于抑制MCC细胞增殖和迁移至关重要.
- 在MCC中由默克尔细胞多重瘤病毒 (MCPyV) 早期基因调节的基因的作用需要进一步阐明.
研究的目的:
- 调查MCC.中MCPyV早期基因调节的NDRG1的上游调节器.
- 探索在MCC治疗中准SET蛋白的治疗潜力.
主要方法:
- 在MCC细胞系 (hTERT-HK-MCPyV和MCPyV+) 和瘤组织中研究了SET蛋白表达.
- 使用小分子抑制剂FTY720来破坏SET-PP2A相互作用.
- 使用短毛RNA (shRNA) 进行SET抑制.
- 评估了细胞增殖,迁移,细胞循环调节剂 (cyclinD1,CDK2) 和殖民地形成.
主要成果:
- 鉴定了SET蛋白 (PP2A的内在抑制剂) 被MCPyV早期基因调节,并且在MCC中由NDRG1上游调节.
- 在MCC皮肤瘤组织中观察到强烈的SET表达.
- 使用FTY720抑制SET-PP2A相互作用,在hTERT-HK-MCPyV细胞中增加了NDRG1表达和抑制了细胞周期调节剂 (cyclinD1,CDK2).
- 通过shRNA和FTY720抑制SET显著降低了MCPyV+MCC细胞中的细胞增殖和殖民地形成.
结论:
- 通过调节NDRG1并影响细胞增殖,SET蛋白在MCC病变发生过程中发挥着重要作用.
- 针对SET-PP2A相互作用,为默克尔细胞癌提供了一个潜在的治疗策略.
- 针对SET蛋白的药物可以为MCC患者提供一种新的治疗方法.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Mitogens and the Cell Cycle
6.5K
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.5K
Negative Regulator Molecules
35.3K
Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
35.3K
Induced Pluripotent Stem Cells
4.0K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.0K
mTOR Signaling and Cancer Progression
3.8K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.8K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K

